Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 251(2023) vom: 15. Juni, Seite 109633 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2023
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Research Support, Non-U.S. Gov't Behçet's disease Dexamethasone Ozurdex Uveitis Vasculitis Glucocorticoids 7S5I7G3JQL |
| Résumé: | Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. To investigate the efficacy and safety of dexamethasone (DEX) implant, Ozurdex ®, as an adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were included in this cross-sectional study and divided into the non-DEX and DEX groups. After >12 months of treatment, the improvement in the fluorescein angiography score and vitritis score was significantly higher in the DEX group than in the non-DEX group. Although the posterior capsule opacification score was exacerbated, the rate of low-dose systemic glucocorticoid was higher and the relapse times were fewer in the DEX group. Therefore, Ozurdex® is an effective and safe option for patients with BU that are refractory to systemic immunosuppressant treatments by controlling vasculitis, stabilizing vitreous inflammation, preventing recurrence, and reducing daily glucocorticoid doses |
|---|---|
| Description: | Date Completed 23.05.2023 Date Revised 16.01.2024 published: Print-Electronic ErratumIn: Clin Immunol. 2024 Feb;259:109893. doi: 10.1016/j.clim.2024.109893. - PMID 38228441 Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2023.109633 |